EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Risdiplam Impact in Treatment Naïve and Non‐Naïve Pediatric and Adult Patients With Spinal Muscular Atrophy

Pak On Patrick Yee, Hayley Hoi Ning Ip, Michael Kwan Leung Yu, Pui Kei Cheng, Wilfred Hing Sang Wong iD, Patrick Pak Hei Ng, Nathan Sheung Tat Kwong, Priscillia Lam, Mei Wun Cheung, Angel Tung, Stephen Chan, Shirley Ng und 5 weitere

European Journal of Neurology · 2026-04 · 33 (4)

DOI: 10.1111/ene.70574 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Neurology, online erschienen am 24.03.2026. Verfasst von Pak On Patrick Yee und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong SAR, China. Hauptthemen laut MEDLINE: Muscular Atrophy, Spinal, Sulfonamides. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Donation Funding.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Risdiplam, an oral disease‐modifying therapy, has demonstrated safety and efficacy in clinical trials, but real‐world data from Asia are limited.

Methods

This prospective study followed 34 symptomatic SMA patients (24 adults, 10 children) over 36 months of risdiplam treatment. The cohort included 5 patients with SMA type 1, 25 with SMA type 2, and 4 with SMA type 3, with ages ranging from 6.9 to 50.9 years. Most (91%) were wheelchair users, and 74% had scoliosis managed by bracing or spinal surgery. Twenty‐five patients (22 adults, 3 children) were treatment naïve, and 9 patients (2 adults, 7 children) switched from nusinersen. Motor function was assessed at baseline, 6, 12, 24, and 36 months using MFM‐32, RULM, ATEND, and HFMSE. In pediatric patients, HRQOL was evaluated using PedsQL Neuromuscular Module and PedsQL Generic Core scale. HRQOL of their parents was assessed with PedsQL Family Impact Module.

Results

After 36 months, MFM‐32 score was significantly improved in those switching therapies [ p = 0.042], while both MFM‐32 and RULM scores were significantly improved in treatment‐naïve group [ p = 0.005 and p = 0.043]. Parents experienced HRQOL gains in their Physical domain (2 years: PedsQL Family Impact Module, p = 0.038). Pediatric patients showed improvement in the Communication domain (3 years: PedsQL Neuromuscular Module, p = 0.042). Risdiplam was generally well tolerated; however, two adults discontinued due to adverse effects. Moreover, two adult patients died during treatment.

Conclusions

This study fills Asian real‐world data gaps, stresses the importance in monitoring in severe SMA, and underscores the need for larger, long‐term safety and efficacy studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Muscular Atrophy, SpinalSulfonamidesHumansFemaleMaleChildAdultAdolescentMiddle AgedYoung AdultQuality of LifeProspective StudiesTreatment OutcomeOligonucleotidesAzo CompoundsPyrimidines

Stichwörter der Autor:innen

health‐related quality of lifemotor functionpatient‐reported outcomerisdiplamspinal muscular atrophy

Substanzen

RisdiplamnusinersenSulfonamidesOligonucleotidesAzo CompoundsPyrimidines

Autor:innen und Institutionen

  • Department of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong SAR, China.
  • Department of Paediatrics and Adolescent Medicine, Queen Mary Hospital, Hong Kong SAR, China.
  • Department of Physiotherapy, Queen Mary Hospital, Hong Kong SAR, China.
  • Allied Health Department (Physiotherapy), Hong Kong Children's Hospital, Hong Kong SAR, China.
  • Department of Paediatrics and Adolescent Medicine, Hong Kong Children's Hospital, Hong Kong SAR, China.
  • Department of Medicine, Queen Mary Hospital, Hong Kong SAR, China.

ORCID-Profile: Wilfred Hing Sang Wong, Sophelia Hoi Shan Chan

Förderung

  • Donation Funding

Zitieren

APA

Yee, P. O. P., Ip, H. H. N., Yu, M. K. L., Cheng, P. K., Wong, W. H. S., Ng, P. P. H., Kwong, N. S. T., Lam, P., Cheung, M. W., Tung, A., Chan, S., Ng, S., Yeung, W. L., Wong, S., Gao, Y., Pang, S., & Chan, S. H. S. (2026). Risdiplam Impact in Treatment Naïve and Non‐Naïve Pediatric and Adult Patients With Spinal Muscular Atrophy. European Journal of Neurology, 33(4). https://doi.org/10.1111/ene.70574

Vancouver

Yee POP, Ip HHN, Yu MKL, Cheng PK, Wong WHS, Ng PPH, et al. Risdiplam Impact in Treatment Naïve and Non‐Naïve Pediatric and Adult Patients With Spinal Muscular Atrophy. European Journal of Neurology. 2026;33(4). doi:10.1111/ene.70574

BibTeX
@article{Yee2026,
  author = {Yee, Pak On Patrick and Ip, Hayley Hoi Ning and Yu, Michael Kwan Leung and Cheng, Pui Kei and Wong, Wilfred Hing Sang and Ng, Patrick Pak Hei and Kwong, Nathan Sheung Tat and Lam, Priscillia and Cheung, Mei Wun and Tung, Angel and Chan, Stephen and Ng, Shirley and Yeung, Wai Lan and Wong, Sheila and Gao, Yuen and Pang, Shirley and Chan, Sophelia Hoi Shan},
  title = {Risdiplam Impact in Treatment Naïve and Non‐Naïve Pediatric and Adult Patients With Spinal Muscular Atrophy},
  journal = {European Journal of Neurology},
  year = {2026},
  volume = {33},
  number = {4},
  doi = {10.1111/ene.70574}
}
Kostenlos starten →